Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotricityBTCY -0.18%20 EBITDA Margin % is 17.01% as of Mar. 2026. GuruFocus rates BTCY with a GF Score™ of 20/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Biotricity ranks better than 56.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biotricity's EBITDA for the
three
months ended in Mar. 2026 was $0.72 Mil. Biotricity's Revenue for the
three
months ended in Mar. 2026 was $4.25 Mil. Therefore, Biotricity's EBITDA margin for the quarter that ended in Mar. 2026 was 17.01%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biotricity EBITDA Margin % Related Terms
Biotricity EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Biotricity's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTCY vs FEED, LUDG, USAQ: EBITDA Margin % Comparison
For the Medical Devices subindustry, Biotricity's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotricity EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biotricity's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotricity (BTCY) has a EBITDA Margin % of 17.01% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biotricity and its competitors. According to the industry distribution chart, Biotricity ranks #351 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is Biotricity's EBITDA Margin % too high?
Biotricity's current EBITDA Margin % is 17.01%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Biotricity's value of 17.01% is 127.7% above this industry median. Based on the distribution chart, Biotricity ranks #351 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biotricity has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's EBITDA Margin % compare to FEED and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Biotricity ranks #351 out of 815 companies for EBITDA Margin %. This puts Biotricity in the upper half of its industry. The industry median EBITDA Margin % is 7.47. Biotricity's value of 17.01% is 127.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotricity's current EBITDA Margin % of 17.01% is 127.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biotricity and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotricity's current EBITDA Margin % is 17.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.11 — trading 71.1% below its estimated fair value. The current EBITDA Margin % is 17.01% and 127.7% above the Medical Devices & Instruments industry median of 7.47. Biotricity's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biotricity (BTCY), the current EBITDA Margin % is 17.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotricity (BTCY) Overvalued in 2026?
Based on GuruFocus' analysis, Biotricity stock appears to be undervalued.
The current stock price of $0.11 is trading 71.1% below its estimated GF Value™ of $0.39.
GuruFocus considers Biotricity to be Possible Value Trap.
Key valuation signals for BTCY:
EBITDA Margin %: 17.01%
GF Value™: $0.39 vs. price of $0.11 (71.1% below fair value)
Industry Position: 127.7% above the Medical Devices & Instruments median (#351 of 815)
No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
20GF Score
Get the complete analysis for BTCY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTCY has been successfully added to your 
